KRAS and cancer: Approximately one-third of all human cancers, including pancreatic, lung, colorectal, and ovarian cancers, are driven by mutations in the RAS oncogenes (KRAS, HRAS, and NRAS), which are upstream molecules in the MAPK/ERK signalling pathway [102,103,104].